Neurotherapeutics

Papers
(The H4-Index of Neurotherapeutics is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-11-01 to 2023-11-01.)
ArticleCitations
FTH1 Inhibits Ferroptosis Through Ferritinophagy in the 6-OHDA Model of Parkinson’s Disease146
Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain119
Septic-Associated Encephalopathy: a Comprehensive Review106
Matrix Metalloproteinases in Acute Intracerebral Hemorrhage66
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease61
Cell Death and Recovery in Traumatic Brain Injury58
Neuropathology of Alzheimer’s Disease56
Vildagliptin Attenuates Huntington’s Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model55
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA54
From Genetic Testing to Precision Medicine in Epilepsy51
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments50
Current Perspectives on Aerobic Exercise in People with Parkinson’s Disease47
Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis46
Central Nervous System Targets: Inhibitory Interneurons in the Spinal Cord46
The Local and Peripheral Immune Responses to Stroke: Implications for Therapeutic Development44
Restless Legs Syndrome: Contemporary Diagnosis and Treatment44
Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson’s Disease44
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin43
Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer’s Disease42
Vascular Cognitive Impairment (VCI)41
Iron and Ferroptosis as Therapeutic Targets in Alzheimer’s Disease40
Aneurysmal Subarachnoid Hemorrhage: an Overview of Inflammation-Induced Cellular Changes40
Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis39
CCR1 Activation Promotes Neuroinflammation Through CCR1/TPR1/ERK1/2 Signaling Pathway After Intracerebral Hemorrhage in Mice39
Therapy of Parkinson’s Disease Subtypes37
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study36
Targeted Perfusion Therapy in Spinal Cord Trauma34
Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders34
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder34
Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies34
Medical Management and Prevention of Motor Complications in Parkinson’s Disease33
FG-4592 Improves Depressive-Like Behaviors through HIF-1-Mediated Neurogenesis and Synapse Plasticity in Rats33
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets32
Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemia–Reperfusion Injury32
Neuromodulation, Specialized Proresolving Mediators, and Resolution of Pain32
0.011858940124512